Anastrozole Tablet, Film Coated
Product Images NDC 59651-236

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 59651-236). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Anastrozole Fig1)

A line graph comparing disease-free survival over time in months for patients treated with anastrozole versus tamoxifen. The vertical axis shows the proportion of patients alive and disease-free, and the horizontal axis represents months up to 90. Patient risk numbers at various time points are tabulated below the graph for both treatments.*

FDA Label Image

Figure 2 (Anastrozole Fig2)

A line graph showing disease-free survival over months, comparing the proportion of patients alive and disease-free between two treatments: anastrozole and tamoxifen. The x-axis represents time in months up to 90, and the y-axis shows the proportion from 0.0 to 1.0. The graph includes patient risk numbers for each treatment group at various time points.*

FDA Label Image

Figure 3 (Anastrozole Fig3)

Kaplan-Meier survival curve showing proportion event-free over time (months) for patients treated with Anastrozole or Tamoxifen. The solid line represents Anastrozole, and the dashed line represents Tamoxifen. The chart includes the number of patients at risk at specified time points up to 120 months.*

FDA Label Image

Figure 4 (Anastrozole Fig4)

A Kaplan-Meier survival curve chart comparing the proportion of event-free patients over time in months for Anastrozole versus Tamoxifen treatment groups. The solid line represents Anastrozole and the dashed line represents Tamoxifen. Patient numbers at risk for each group are listed below the timeline axis from 0 to 120 months.*

FDA Label Image

Figure 5 (Anastrozole Fig5)

A Kaplan-Meier curve chart comparing the proportion of patients not progressing over time in months between Anastrozole and Tamoxifen treatment groups. The chart includes a timeline from 0 to 42 months and shows the number of patients at risk for each treatment at various time points.*

FDA Label Image

Figure 6 (Anastrozole Fig6)

A line graph showing the proportion of patients not progressing over time in months compared between two randomized treatments, Anastrozole and Tamoxifen. The x-axis represents time to progression in months up to 40, and the y-axis represents the proportion not progressing from 0 to 1. Two lines, solid for Anastrozole and dashed for Tamoxifen, depict patient outcomes with corresponding numbers at risk listed below the x-axis.*

FDA Label Image

Package Label-principal Display Panel – 1 mg ((30 Tablets Bottle))

Anastrozole Tablets USP 1 mg film-coated tablets packaging label. The label indicates a package size of 30 tablets. It includes the NDC 59651-236-30 and is distributed by Aurobindo Pharma USA, Inc. The label features storage instructions and a barcode on the right side.*

FDA Label Image

Chemical Structure (Anastrozole Str)

Chemical structure diagram of Anastrozole, showing its molecular framework including a triazole ring attached to a substituted benzene ring with two cyano and two methyl groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.